Press Release: May 31, 2024
Novelna Inc. Expands Advisory Board with Strategic and Business Development Leaders
Palo Alto, California – Novelna, a proteomics-based liquid biopsy startup, is pleased to welcome two distinguished advisors to its advisory board. This strategic move aims to accelerate Novelna's product development efforts and enhance its potential market position.
The new advisors include:
Linda Mansolillo, MBA MMAS – Strategic Commercial Partnerships
Linda is a healthcare executive and Lieutenant Colonel in the U.S. Air Force Reserve, with demonstrated expertise in developing strategy, opening new markets, and building commercial partnerships within the biotechnology and diagnostic healthcare sectors. She brings invaluable insights into product strategy and commercialization, sustainable and scalable growth, business development and strategic partnerships, human capital and compensation strategies, and crisis response leadership and management. Her diverse experience and leadership skills will be instrumental in driving Novelna's strategic initiatives and growth.
Srini Kodali, MBA – Corporate and Business Development
Srini is a well-versed professional in the life sciences sector, with a strong focus on oncology diagnostics and life science tools. He will contribute to Novelna’s initiatives through his expertise in molecular diagnostics, liquid biopsy, multi-omics approaches, and mass spec-based proteomics for biomarker discovery. He has a proven track record of working cross-functionally to formulate and execute business development strategies, as well as forge deep collaborations and negotiate partnerships that advance life sciences research and clinical markets.
Ashkan Afshin, CEO of Novelna, expressed enthusiasm about the new appointments, stating, "We are thrilled to welcome such distinguished professionals to our advisory board. Their combined expertise and strategic guidance will be invaluable as we continue to advance our mission."
The addition of these advisors reflects Novelna's commitment to leveraging top-tier talent to achieve its long-term goals. Each advisor brings a unique perspective and a wealth of experience that will support the company in navigating the complexities of the diagnostics market.
For more information about Novelna and its advisory board, please visit www.novelna.com.
Contact Information: info@novelna.com
About Novelna Inc.: Novelna is a proteomics-based liquid biopsy startup, transforming cancer diagnostics. Our mission is simple: ensure early disease detection is not a privilege, but a right for all. By advancing diagnostic technologies, we are committed to securing a healthier and brighter future globally.